Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-RAD LABORATORIES, INC.BIO BIO.B · Entity 2247 | Director | September 04, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-RAD LABORATORIES, INC.
Report date September 04, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Bio-Rad A Common StockSEC Table I · non-derivative | Direct | 1,734 |
Ending reported balance
After 2026-09-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-05 · Exercise / conversion · Acquired 228 · Balance 1,758 F1: Shares of Class A common stock acquired on the vesting of restricted stock units. Row 2 · 2026-09-05 · Tax withholding · Disposed 82 · Balance 1,676 Row 3 · 2026-09-06 · Exercise / conversion · Acquired 92 · Balance 1,768 F1: Shares of Class A common stock acquired on the vesting of restricted stock units. Row 4 · 2026-09-06 · Tax withholding · Disposed 34 · Balance 1,734 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 719 |
Reported balance
After 2026-09-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-04 · Grant · Acquired 719 · Balance 719 F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3: The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 686 |
Reported balance
After 2026-09-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-05 · Exercise / conversion · Disposed 228 · Balance 686 F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 185 |
Reported balance
After 2026-09-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-06 · Exercise / conversion · Disposed 92 · Balance 185 F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
F3: The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter.
F4: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2023 Filed Sep 6, 2023 16:58 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 12 | $394.60 | $4,735.20 |
DisclosureSEC source: 0001062993-23-017642 · form4.xml · nonDerivative · entry 4 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,069 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:58 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 30 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017642 · form4.xml · nonDerivative · entry 3 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:58 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 17 | $394.60 | $6,708.20 |
DisclosureSEC source: 0001062993-23-017642 · form4.xml · nonDerivative · entry 2 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,051 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:58 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 41 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017642 · form4.xml · nonDerivative · entry 1 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| November 07, 2022 Filed Nov 28, 2022 19:15 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GiftBio-Rad B Common Stock | 42 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-022795 · form4.xml · nonDerivative · entry 1 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,890 Read SEC document |
| September 05, 2022 Filed Sep 7, 2022 18:22 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 80 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019288 · form4.xml · derivative · entry 12 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 80 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: On September 5, 2017, the reporting person was granted 400 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On September 5, 2017, the reporting person was granted 400 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 05, 2022 Filed Sep 7, 2022 18:22 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 33 | $478.32 | $15,784.56 |
DisclosureSEC source: 0001062993-22-019288 · form4.xml · nonDerivative · entry 8 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027 Read SEC document |
| September 05, 2022 Filed Sep 7, 2022 18:22 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 80 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019288 · form4.xml · nonDerivative · entry 7 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 04, 2022 Filed Sep 7, 2022 18:22 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 82 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019288 · form4.xml · derivative · entry 11 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82 Underlying: Bio-Rad A Common Stock · 82 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 4, 2018, the reporting person was granted 410 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 4, 2018, the reporting person was granted 410 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 04, 2022 Filed Sep 7, 2022 18:22 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 34 | $478.32 | $16,262.88 |
DisclosureSEC source: 0001062993-22-019288 · form4.xml · nonDerivative · entry 6 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 980 Read SEC document |
| September 04, 2022 Filed Sep 7, 2022 18:22 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 82 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019288 · form4.xml · nonDerivative · entry 5 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 03, 2022 Filed Sep 7, 2022 18:22 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 56 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019288 · form4.xml · derivative · entry 10 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112 Underlying: Bio-Rad A Common Stock · 56 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On September 3, 2019, the reporting person was granted 279 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On September 3, 2019, the reporting person was granted 279 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 03, 2022 Filed Sep 7, 2022 18:22 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 23 | $478.32 | $11,001.36 |
DisclosureSEC source: 0001062993-22-019288 · form4.xml · nonDerivative · entry 4 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 932 Read SEC document |
| September 03, 2022 Filed Sep 7, 2022 18:22 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 56 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019288 · form4.xml · nonDerivative · entry 3 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 18:22 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 43 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019288 · form4.xml · derivative · entry 9 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88 Underlying: Bio-Rad A Common Stock · 43 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 174 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 174 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 18:22 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 18 | $478.32 | $8,609.76 |
DisclosureSEC source: 0001062993-22-019288 · form4.xml · nonDerivative · entry 2 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 899 Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 18:22 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 43 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019288 · form4.xml · nonDerivative · entry 1 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 18:07 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 30 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019200 · form4.xml · derivative · entry 4 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92 Underlying: Bio-Rad A Common Stock · 30 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 122 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 122 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 18:07 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 167 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019200 · form4.xml · derivative · entry 3 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167 Underlying: Bio-Rad A Common Stock · 167 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 18:07 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 12 | $486.25 | $5,835.00 |
DisclosureSEC source: 0001062993-22-019200 · form4.xml · nonDerivative · entry 2 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 874 Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 18:07 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 30 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019200 · form4.xml · nonDerivative · entry 1 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.